Losartan

Generic Name: Losartan

Brand Names: Hyzaar, Cozaar

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃ClN_₆O

CAS Number: 114798-26-4

Unique Ingredient Identifier: JMS50MPO89

Background: Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication: Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions: Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Clinical Trials

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2013-12-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 805

Registration Number: NCT00274638

Locations: 🇺🇸
Herron Medical Center, Ltd., Chicago, Illinois, United States
🇺🇸
Midwest Institute for Clinical Research Inc., Indianapolis, Indiana, United States
🇺🇸
nTouch Research, Houston, Texas, United States

and more 50 locations

Prevention of Decompensation in Liver Cirrhosis

Phase 4

Conditions: Alcoholic Liver Cirrhosis
Ascites

First Posted Date: 2005-10-14

Last Posted Date: 2005-10-14

Lead Sponsor: Odense University Hospital

Target Recruit Count: 100

Registration Number: NCT00239096

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Treatment of Supine Hypertension in Autonomic Failure

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Clonidine
Drug: Nitroglycerin transdermal
Drug: Dipyridamole/ Aspirin (Aggrenox)
Drug: Desmopressin (DDAVP)
Drug: Sildenafil
Drug: Nifedipine
Drug: Hydralazine
Drug: Hydrochlorothiazide
Drug: Bosentan
Drug: Diltiazem
Drug: Eplerenone
Drug: guanfacine
Dietary Supplement: L-arginine
Drug: captopril
Drug: carbidopa
Drug: losartan
Drug: metoprolol tartrate
Drug: nebivolol hydrochloride
Drug: prazosin hydrochloride
Drug: tamsulosin hydrochloride
Other: Head-up tilt.
Drug: aliskiren
Other: Local heat stress

First Posted Date: 2005-09-22

Last Posted Date: 2017-10-13

Lead Sponsor: Vanderbilt University

Target Recruit Count: 152

Registration Number: NCT00223717

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension
Left Ventricular Hypertrophy
Overweight

Interventions: Drug: Aliskiren 150/300 mg
Drug: Losartan 50/100 mg
Drug: Aliskiren placebo
Drug: Losartan 50/100 mg placebo

First Posted Date: 2005-09-22

Last Posted Date: 2011-05-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 460

Registration Number: NCT00219141

Locations: 🇦🇷
sites in Argentina, Argentina, Argentina
🇩🇪
sites in Germany, Germany, Germany
🇪🇸
sites in Spain, Spain, Spain

and more 6 locations

Hypertension Control Based on Home Blood Pressure

Phase 4

Conditions: Hypertension

Interventions: Drug: Amlodipine, Losartan

First Posted Date: 2005-09-20

Last Posted Date: 2008-04-22

Lead Sponsor: Ministry of Health, Labour and Welfare, Japan

Target Recruit Count: 2600

Registration Number: NCT00198562

Locations: 🇯🇵
National Cardiovascular Center, Suita, Osaka, Japan

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Phase 4

Completed

Conditions: Metabolic Syndrome
Hypertension
Insulin Resistance

First Posted Date: 2005-09-16

Last Posted Date: 2005-12-23

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 60

Registration Number: NCT00185094

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Phase 4

Completed

Conditions: Hypertension
Diabetic Nephropathies

First Posted Date: 2005-09-15

Last Posted Date: 2023-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 860

Registration Number: NCT00168857

Locations: 🇲🇽
Fracc. Magallanes, Acapulco Guerrero, Mexico
🇺🇸
VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
🇹🇭
Pramongkutklao Hospital, Bangkok, Thailand

and more 62 locations